This study identifies 8 novel recurrent mutations in the SARS-CoV-2 genome, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403, and 28881. These mutations are distributed across different geographic regions, with some predominantly found in Europe and others in North America. A silent mutation in the RdRp gene was first observed in the UK on February 9, 2020, while a different mutation in RdRp was first observed in Italy on February 20, 2020. Viruses with RdRp mutations have a median of 3 point mutations, compared to 1 mutation in those without RdRp mutations (p < 0.001). The study suggests that the virus is evolving, with European and North American strains coexisting, each with distinct mutation patterns. The RdRp enzyme is a key target for antiviral drugs, and mutations in this gene may affect drug resistance and viral pathogenicity. The findings highlight the importance of studying SARS-CoV-2 RdRp mutations to understand drug resistance and mortality rates. The study analyzed 220 SARS-CoV-2 genomes from the GISAID database, comparing them to the reference genome. The results indicate that mutations in RdRp may influence viral replication and drug resistance, emphasizing the need for further research into the role of these mutations in viral evolution and treatment strategies.This study identifies 8 novel recurrent mutations in the SARS-CoV-2 genome, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403, and 28881. These mutations are distributed across different geographic regions, with some predominantly found in Europe and others in North America. A silent mutation in the RdRp gene was first observed in the UK on February 9, 2020, while a different mutation in RdRp was first observed in Italy on February 20, 2020. Viruses with RdRp mutations have a median of 3 point mutations, compared to 1 mutation in those without RdRp mutations (p < 0.001). The study suggests that the virus is evolving, with European and North American strains coexisting, each with distinct mutation patterns. The RdRp enzyme is a key target for antiviral drugs, and mutations in this gene may affect drug resistance and viral pathogenicity. The findings highlight the importance of studying SARS-CoV-2 RdRp mutations to understand drug resistance and mortality rates. The study analyzed 220 SARS-CoV-2 genomes from the GISAID database, comparing them to the reference genome. The results indicate that mutations in RdRp may influence viral replication and drug resistance, emphasizing the need for further research into the role of these mutations in viral evolution and treatment strategies.